Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vaccinex, Inc.

http://www.vaccinex.com

Latest From Vaccinex, Inc.

Aduhelm Approval Boosts Other Alzheimer’s Drug Developers

Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.

Approvals Business Strategies

Roche Shelves Phase III Huntington's Candidate Tominersen

Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.

Companies Clinical Trials

Deal Watch: ICON, PRA Health Form Massive CRO In $12bn Merger

Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia

Deals M & A

Roche Confident But Cautious On Alzheimer's Hopeful

The Swiss major has highlighted two high-risk, high-reward neurodegenerative programs that could be transformative for the treatment of Alzheimer's and Huntington's disease.

Neurology Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register